Leukaemia Trial, Recruiting NCT05130138 Sponsor: Centre Hospitalier Universitaire de Saint Etienne Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT05130138
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are adults (18 years of age or older).
  • People who are covered by a social security scheme (such as health insurance through a social security system).
  • People who have been diagnosed with Chronic Myeloid Leukemia (a type of blood cancer) and are currently taking one of the following medicines: Imatinib, Nilotinib, Dasatinib, or Bosutinib.
  • People whose blood cancer is still detectable at a certain level — specifically, where the amount of cancer-related genetic material in the blood has not dropped below a level called "4.5 Log" (confirm with trial site for what this means in your specific situation).

Who may not be able to join:

  • People who do not have the legal or mental capacity to make their own decisions about participating.
  • People who are unable to read and/or write in French.
  • People who are currently taking the medicine Ponatinib.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xavier SIMOENS, MD, PhD, CHU de Saint-Etienne

Phone: 0477822875

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Registry
ClinicalTrials.gov
Start date
27 January 2022
Est. completion
1 November 2025

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Number of patients for whom pharmaceutical interventions have been done

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov